You are here: Industry Insights > Novartis

News List

FDA grants breakthrough therapy status for Novartis' crizanlizumab to prevent vaso-occlusive crises in sickle cell disease firstwordpharma
January 09, 2019
Novartis announced Tuesday that the FDA granted crizanlizumab a breakthrough therapy designation for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell?disease (SCD). Samit Hirawat, head of oncology global drug de
Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises fiercepharma
January 09, 2019
Novartis' first-ever CAR-T cell therapy may have been hamstrung by early manufacturing problems, but the company still figures it can build a?cell and gene therapy platform strong enough to deliver success not only with Kymriah?but also a full "game board
Verily pockets $1B with eyes on partnerships, M&A fiercebiotech
January 07, 2019
Six weeks after canning its Novartis-partnered?glucose-sensing contact lens project, Verily is?raising?a $1 billion round that will power new partnerships, “global business development opportunities” and potential acquisitions.....
Swiss biotech Oculis raises cash, nabs Novartis eye drug in extended series B fiercebiotech
January 07, 2019
Hoping to push on with its work on next-gen eye treatments, Oculis has raised an extra CHF 15 million ($15.2 million) as it looks to fellow native Swiss biopharma Novartis for its next project....
Ribon Therapeutics gains Novartis, J&J backing for monoPARP work fiercebiotech
January 07, 2019
The once highly secretive Ribon Therapeutics has come out with a chunky series B with a focus on monoPARPs against cancer, inflammatory disorders and neurodegenerative diseases.....
Novartis offers to acquire CellforCure cphi-online
January 02, 2019
Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.
Midphase failure of Novartis’ NASH drug crushes Conatus fiercebiotech
December 29, 2018
A phase 2b trial of Conatus Pharmaceuticals’ emricasan has?missed?its primary endpoint. The setback wiped 55% off Conatus’ stock in premarket trading as investors digested the implications of a second midphase failure in eight months.....
Novartis Makes Offer for French CDMO contractpharma
December 27, 2018
Novartis?has made an offer to acquire?CellforCurefrom LFB. CellforCure, a French company, is one of the first and largest contract development and manufacturing organizations (CDMO) producing cell and gene therapies in Europe.
Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask fiercepharma
December 26, 2018
Novartis released some new data on CAR-T drug Kymriah this month that it hopes will improve the uptake of the drug. But Novartis also continues to wrestle with manufacturing issues that have kept some doses
Novartis offers to buy Kymriah manufacturer pharmaphorum
December 24, 2018
Following its success in the burgeoning area of CAR-T therapies, Novartis is looking to strengthen its cell and gene manufacturing capabilities by offering to acquire CDMO CellforCure, manufacturers of its CAR-T drug Kymriah.